Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × tanespimycin × Genitourinary × Clear all

Phase

Status

Sponsor Class

NIH 4 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Sarcoma 3 Plasma cell 3 Other hematologic neoplasm 3 Breast 3 Gastrointestinal 2 Other solid neoplasm 1 Lymphoid 1 Genitourinary 1 Dermatologic 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 149 Prednisone 119 enzalutamide 112 Docetaxel 111 Abiraterone Acetate 85 Nivolumab 84 Gemcitabine 63 Sunitinib 55 Leuprolide 46 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 44 atezolizumab 42 Cisplatin 42 abiraterone 39 Ipilimumab 36 Sorafenib 35 Carboplatin 35 apalutamide 34 radium Ra 223 dichloride 33 Everolimus 32 darolutamide 30 Paclitaxel 30 cabozantinib 29 avelumab 27 pazopanib 26 Prednisolone 26 Axitinib 26 bicalutamide 25 Bevacizumab 25 enfortumab vedotin 23 cabazitaxel 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00564928 2012-12-11

IPI-504-04

Infinity Pharmaceuticals, Inc.

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡